Logo image of VNDA

VANDA PHARMACEUTICALS INC (VNDA) Stock Fundamental Analysis

USA - NASDAQ:VNDA - US9216591084 - Common Stock

4.49 USD
-0.03 (-0.66%)
Last: 9/19/2025, 8:00:02 PM
4.57 USD
+0.08 (+1.78%)
After Hours: 9/19/2025, 8:00:02 PM
Fundamental Rating

3

Overall VNDA gets a fundamental rating of 3 out of 10. We evaluated VNDA against 541 industry peers in the Biotechnology industry. There are concerns on the financial health of VNDA while its profitability can be described as average. VNDA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

In the past year VNDA has reported negative net income.
In the past year VNDA has reported a negative cash flow from operations.
VNDA had positive earnings in 4 of the past 5 years.
Of the past 5 years VNDA 4 years had a positive operating cash flow.
VNDA Yearly Net Income VS EBIT VS OCF VS FCFVNDA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

1.2 Ratios

Looking at the Return On Assets, with a value of -10.71%, VNDA belongs to the top of the industry, outperforming 83.18% of the companies in the same industry.
With an excellent Return On Equity value of -13.76%, VNDA belongs to the best of the industry, outperforming 87.62% of the companies in the same industry.
Industry RankSector Rank
ROA -10.71%
ROE -13.76%
ROIC N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
VNDA Yearly ROA, ROE, ROICVNDA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 -10 20 -20

1.3 Margins

VNDA has a better Gross Margin (94.40%) than 93.90% of its industry peers.
In the last couple of years the Gross Margin of VNDA has remained more or less at the same level.
The Profit Margin and Operating Margin are not available for VNDA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.4%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
VNDA Yearly Profit, Operating, Gross MarginsVNDA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 60 80

More info and screens

3

2. Health

2.1 Basic Checks

VNDA does not have a ROIC to compare to the WACC, probably because it is not profitable.
VNDA has more shares outstanding than it did 1 year ago.
VNDA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, VNDA has a worse debt to assets ratio.
VNDA Yearly Shares OutstandingVNDA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
VNDA Yearly Total Debt VS Total AssetsVNDA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

Based on the Altman-Z score of 0.95, we must say that VNDA is in the distress zone and has some risk of bankruptcy.
VNDA has a better Altman-Z score (0.95) than 63.22% of its industry peers.
VNDA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.01, VNDA perfoms like the industry average, outperforming 45.10% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 0.95
ROIC/WACCN/A
WACC9.65%
VNDA Yearly LT Debt VS Equity VS FCFVNDA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M 500M

2.3 Liquidity

A Current Ratio of 3.25 indicates that VNDA has no problem at all paying its short term obligations.
VNDA has a worse Current ratio (3.25) than 61.18% of its industry peers.
VNDA has a Quick Ratio of 3.23. This indicates that VNDA is financially healthy and has no problem in meeting its short term obligations.
VNDA has a Quick ratio (3.23) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.25
Quick Ratio 3.23
VNDA Yearly Current Assets VS Current LiabilitesVNDA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for VNDA have decreased strongly by -494.74% in the last year.
The Revenue has grown by 11.78% in the past year. This is quite good.
VNDA shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -2.64% yearly.
EPS 1Y (TTM)-494.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
Revenue 1Y (TTM)11.78%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%4.19%

3.2 Future

Based on estimates for the next years, VNDA will show a small growth in Earnings Per Share. The EPS will grow by 6.83% on average per year.
Based on estimates for the next years, VNDA will show a small growth in Revenue. The Revenue will grow by 1.13% on average per year.
EPS Next Y-475.88%
EPS Next 2Y-82.36%
EPS Next 3Y6.83%
EPS Next 5YN/A
Revenue Next Year12.81%
Revenue Next 2Y24.69%
Revenue Next 3Y26.56%
Revenue Next 5Y1.13%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
VNDA Yearly Revenue VS EstimatesVNDA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 100M 200M 300M 400M
VNDA Yearly EPS VS EstimatesVNDA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 1 -1 2

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

VNDA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VNDA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
VNDA Price Earnings VS Forward Price EarningsVNDA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
VNDA Per share dataVNDA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-82.36%
EPS Next 3Y6.83%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for VNDA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

VANDA PHARMACEUTICALS INC

NASDAQ:VNDA (9/19/2025, 8:00:02 PM)

After market: 4.57 +0.08 (+1.78%)

4.49

-0.03 (-0.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)07-31 2025-07-31/bmo
Earnings (Next)11-04 2025-11-04
Inst Owners78.97%
Inst Owner Change1.78%
Ins Owners7.03%
Ins Owner Change6.65%
Market Cap265.31M
Analysts80
Price Target12.92 (187.75%)
Short Float %8.49%
Short Ratio9.74
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.3%
Min EPS beat(2)-26.44%
Max EPS beat(2)17.84%
EPS beat(4)3
Avg EPS beat(4)15.96%
Min EPS beat(4)-26.44%
Max EPS beat(4)45.98%
EPS beat(8)6
Avg EPS beat(8)5.71%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.57%
Min Revenue beat(2)-5.56%
Max Revenue beat(2)8.7%
Revenue beat(4)1
Avg Revenue beat(4)-0.51%
Min Revenue beat(4)-5.56%
Max Revenue beat(4)8.7%
Revenue beat(8)3
Avg Revenue beat(8)0.35%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-20.35%
EPS NQ rev (3m)-34.65%
EPS NY rev (1m)0%
EPS NY rev (3m)-20.98%
Revenue NQ rev (1m)-1.01%
Revenue NQ rev (3m)0.12%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.3
P/FCF N/A
P/OCF N/A
P/B 0.55
P/tB 0.71
EV/EBITDA N/A
EPS(TTM)-1.13
EYN/A
EPS(NY)-1.06
Fwd EYN/A
FCF(TTM)-1.12
FCFYN/A
OCF(TTM)-1.1
OCFYN/A
SpS3.44
BVpS8.23
TBVpS6.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -10.71%
ROE -13.76%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.4%
FCFM N/A
ROA(3y)-0.5%
ROA(5y)1.69%
ROE(3y)-0.62%
ROE(5y)1.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.39%
GM growth 5Y1.12%
F-Score3
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 13.98%
Cap/Sales 0.55%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.25
Quick Ratio 3.23
Altman-Z 0.95
F-Score3
WACC9.65%
ROIC/WACCN/A
Cap/Depr(3y)14.89%
Cap/Depr(5y)25.49%
Cap/Sales(3y)0.24%
Cap/Sales(5y)0.33%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-494.74%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-475%
EPS Next Y-475.88%
EPS Next 2Y-82.36%
EPS Next 3Y6.83%
EPS Next 5YN/A
Revenue 1Y (TTM)11.78%
Revenue growth 3Y-9.56%
Revenue growth 5Y-2.64%
Sales Q2Q%4.19%
Revenue Next Year12.81%
Revenue Next 2Y24.69%
Revenue Next 3Y26.56%
Revenue Next 5Y1.13%
EBIT growth 1Y-210.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year7.55%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-263.14%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-258.43%
OCF growth 3YN/A
OCF growth 5YN/A